Letter by Heuts et al Regarding Article, “Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”
Circulation · 2024
DOI: 10.1161/circulationaha.123.066934 ↗Kurz gefasst
Leserbrief in der Zeitschrift Circulation, 2024. Verfasst von Samuel Heuts und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Maastricht University Medical Center, the Netherlands (S.H.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Fractional Flow Reserve, Myocardial, Percutaneous Coronary Intervention. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Maastricht University Medical Center, the Netherlands (S.H.).
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, the Netherlands (S.H.).
- Division of Cardiac Surgery, CHUV, Lausanne University Hospital, Switzerland (P.O.M.).
- Department of Cardiac Surgery, University Heart Center, University Hospital Bern, Switzerland (M.S.).
ORCID-Profile: Samuel Heuts, Patrick O Myers, Matthias Siepe
Zitieren
APA
Heuts, S., Myers, P. O., & Siepe, M. (2024). Letter by Heuts et al Regarding Article, “Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”. Circulation. https://doi.org/10.1161/circulationaha.123.066934
Vancouver
Heuts S, Myers PO, Siepe M. Letter by Heuts et al Regarding Article, “Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”. Circulation. 2024. doi:10.1161/circulationaha.123.066934
BibTeX
@article{Heuts2024,
author = {Heuts, Samuel and Myers, Patrick O and Siepe, Matthias},
title = {Letter by Heuts et al Regarding Article, “Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”},
journal = {Circulation},
year = {2024},
doi = {10.1161/circulationaha.123.066934}
}
EUVIMED